1-Methyl-4-phenylpyridinium ion (MPP+) triggers experimental or secondary parkinsonism, while MAO-B enables its transformation from 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP)14. This evidence concerns the gene MAOB and Parkinson disease.